Search Results - "Gudger, Amy"

Infections in relapsed myeloma patients treated with isatuximab plus pomalidomide and dexamethasone during the COVID-19 pandemic: Initial results of a UK-wide real-world study by Djebbari, Faouzi, Rampotas, Alexandros, Vallance, Grant, Panitsas, Fotios, Basker, Nanda, Sangha, Gina, Salhan, Beena, Karim, Farheen, Firas, Al-Kaisi, Gudger, Amy, Ngu, Loretta, Poynton, Matt, Lam, Ho Pui Jeff, Morgan, Lowri, Yang, Laura, Young, Jennifer, Walker, Mairi, Tsagkaraki, Ismini, Anderson, Laura, Chauhan, Saleena Rani, Maddams, Rebecca, Soutar, Richard, Triantafillou, Margarita, Prideaux, Steve, Obeidalla, Abubaker, Eyre, Toby A., Bygrave, Ceri, Basu, Supratik, Ramasamy, Karthik

“…There are no real-world data describing infection morbidity in relapsed/refractory myeloma (RRMM) patients treated with anti-CD38 isatuximab in combination…”
Get full text

Efficacy of Isatuximab With Pomalidomide and Dexamethasone in Relapsed Myeloma: Results of a UK‐Wide Real‐World Dataset by Djebbari, Faouzi, Rampotas, Alexandros, Vallance, Grant, Panitsas, Fotios, Basker, Nanda, Sangha, Gina, Salhan, Beena, Karim, Farheen, Al‐Kaisi, Firas, Gudger, Amy, Ngu, Loretta, Poynton, Matt, Lam, Ho Pui Jeff, Morgan, Lowri, Yang, Laura, Young, Jennifer, Walker, Mairi, Tsagkaraki, Ismini, Anderson, Laura, Chauhan, Saleena Rani, Maddams, Rebecca, Soutar, Richard, Triantafillou, Margarita, Prideaux, Steve, Obeidalla, Abubaker, Bygrave, Ceri, Basu, Supratik, Ramasamy, Karthik

“…Real‐world data on the efficacy and tolerability of isatuximab with pomalidomide and dexamethasone (IsaPomDex) in relapsed/refractory myeloma patients have not…”
Get full text

Isatuximab with Pomalidomide and Dexamethasone Provides Comparable Efficacy Outcomes in Frail Routine Care Myeloma Patients in a UK-Wide Cohort by Rampotas, Alexandros, Rampotas, Alexandros, Vallance, Grant, Panitsas, Fotios, Basker, Nanda, Sangha, Gina, Salhan, Beena, Karim, Farheen, Al-Kaisi, Firas, Gudger, Amy, Ngu, Loretta, Poynton, Matt, Lam, Ho Pui Jeff, Morgan, Lowri, Yang, Laura, Young, Jennifer, Walker, Mairi, Tsagkaraki, Ismini, Anderson, Laura, Chauhan, Saleena Rani, Maddams, Rebecca, Soutar, Richard, Triantafillou, Margarita, Prideaux, Steve, Obeidalla, Abubaker, Bygrave, Ceri, Basu, Supratik, Ramasamy, Karthik

Get full text

Frailty subgroup analysis of isatuximab with pomalidomide and dexamethasone in a UK‐wide real‐world cohort of relapsed myeloma patients by Djebbari, Faouzi, Rampotas, Alexandros, Vallance, Grant, Panitsas, Fotios, Basker, Nanda, Sangha, Gina, Salhan, Beena, Karim, Farheen, Al‐Kaisi, Firas, Gudger, Amy, Ngu, Loretta, Poynton, Matt, Lam, Ho Pui Jeff, Morgan, Lowri, Yang, Laura, Young, Jennifer, Walker, Mairi, Tsagkaraki, Ismini, Anderson, Laura, Chauhan, Saleena Rani, Maddams, Rebecca, Soutar, Richard, Triantafillou, Margarita, Prideaux, Steve, Obeidalla, Abubaker, Eyre, Toby A., Bygrave, Ceri, Kothari, Jaimal, Basu, Supratik, Ramasamy, Karthik

Get full text

Efficacy Outcomes of Isatuximab with Pomalidomide and Dexamethasone Are Comparable to (ICARIA-MM) Trial Data: Initial Results of a UK-Wide Real-World Study of Relapsed Myeloma Patients by Djebbari, Faouzi, Vallance, Grant, Basker, Nanda, Panitsas, Fotios, Rampotas, Alexandros, Sangha, Gina, Salhan, Beena, Karim, Farheen, Al-kaisi, Firas, Gudger, Amy, Ngu, Loretta, Poynton, Matt, Lam, Ho Pui Jeff, Morgan, Lowri, Yang, Laura, Young, Jennifer, Walker, Mairi, Tsagkaraki, Ismini, Anderson, Laura, Chauhan, Saleena Rani, Maddams, Rebecca, Stirton, Lesley, Triantafillou, Margarita, Prideaux, Steve, Obeidalla, Abubaker, Bygrave, Ceri, Basu, Supratik, Ramasamy, Karthik

“…Objective: Real-world data on the efficacy and tolerability of isatuximab with pomalidomide and dexamethasone (IsaPomDex) in relapsed/refractory myeloma (RRMM)…”
Get full text

Very early lineage-specific chimerism after reduced intensity stem cell transplantation is highly predictive of clinical outcome for patients with myeloid disease by Kinsella, Francesca A.M., Inman, Charlotte F., Gudger, Amy, Chan, Yuen T., Murray, Duncan J., Zuo, Jianmin, McIlroy, Graham, Nagra, Sandeep, Nunnick, Jane, Holder, Kathy, Wall, Kerry, Griffiths, Mike, Craddock, Charles, Nikolousis, Emmanouil, Moss, Paul, Malladi, Ram

“…[Display omitted] •Chimerism within PBMC and T cells at day 50 after allo-SCT defines three groups.•Relapse risk for myeloid disease is high if mixed chimerism…”
Get full text

Split Mixed Donor Chimerism Early after T-Cell Depleted Reduced Intensity Conditioned Allogeneic Haematopoietic Stem Cell Transplantation Predicts Survival by Kinsella, Francesca A M, Gudger, Amy, Inman, Charlotte F, Mc Ilroy, Graham, Nagra, Sandeep, Nunnick, Jane, Waldron, Dave, Wall, Kerry, Griffiths, Mike, Moss, Paul, Craddock, Charles, Nikolousis, Emmanouil, Malladi, Ram

“…▪ The significance of mixed donor chimerism as a hallmark of an unsuccessful graft versus leukaemia effect and disease relapse is unclear. Whilst some studies…”
Get full text

Full Donor T Cell Chimerism Predicts Transplant Outcomes In High Risk AML But Not In Intermediate Risk AML After a T-Deplete Alemtuzumab Conditioned Transplant by Gudger, Amy, Murthy, Vidhya, Murray, Duncan J, Bailiff, Ben, Mushkbar, Maria, Lancashire, Jonathan ray, Nicolson, Phillip, Holder, Kathy, Baker, Lynda, Bratby, Lynn, Kishore, Bhuvan, Lovell, Richard, Paneesha, Shankaranarayana, Emmanouil, Nikolousis

“…Reduced intensity conditioning (RIC) T-deplete regimens are now widely used as a platform to deliver a potentially curative T cell mediated…”
Get full text